This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cytocell Ltd Introduces New Haematology FISH Probes For Chronic Lymphocytic Leukaemia (CLL)

Chromosomal abnormalities have been shown to play a major role in disease evolution in several haematological malignancies. Fluorescence In Situ Hybridisation (FISH), using locus-specific probes, which are capable of defining numerical and structural chromosome changes, has now become a routine diagnostic test in the clinical laboratory and the technique has thus been shown to be useful in the management of cancer patients.

About Cytocell Ltd.

Cytocell is a leading European developer and manufacturer of FISH probes for use in both routine cytogenetics and in the analysis and classification of Cancers. The Company's products are well established in Cytogenetics as the Company is celebrating its 20 th year of supplying them to this market. More recently, the Company has focused on developing products for Oncology and now has a catalogue of some 350 products for Cytogenetics, Haematology and Solid Tumour analysis as well as developing custom FISH probes for customers with specific interests under the myProbes ® brand. Cytocell's products are available through a well established distributor network, covering more than 60 countries worldwide. Cytocell's FISH probe service is currently proving to be invaluable to cancer researchers and clinicians worldwide.

Cytocell's news releases and other information are available on the company's Web site at

For further enquiries, please contact:

Stewart Kennedy, Sales & Marketing Director Tel: +44(0)7860-455527

SOURCE Cytocell Ltd

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs